Breakthrough Therapy Designation for Pfizer bispecific antibody
A bispecific antibody for multiple myeloma gets Breakthrough Therapy Designation based on 61 percent overall response trial data.
List view / Grid view
A bispecific antibody for multiple myeloma gets Breakthrough Therapy Designation based on 61 percent overall response trial data.
Through a clinical trial, Cleveland researchers have identified how rivaroxaban reduces blood clots in cancer patients and also decreases related deaths...